V V McLaughlin
Overview
Explore the profile of V V McLaughlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khanna D, Tan M, Furst D, Hill N, McLaughlin V, Silver R, et al.
Clin Exp Rheumatol
. 2013 Dec;
32(6 Suppl 86):S-21-7.
PMID: 24295227
Objectives: The aim of this study was to utilise the Quality Enhancement Research Initiative in Systemic Sclerosis (QuERI-SSc) to measure and reduce a perceived gap in the diagnosis of pulmonary...
2.
McLaughlin V
Eur Respir Rev
. 2011 Dec;
20(122):262-9.
PMID: 22130819
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease characterised by vascular proliferation and remodelling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance,...
3.
Tapson V, McLaughlin V, Gomberg-Maitland M, Widlitz A, Krichman A, Laliberte K, et al.
J Vasc Access
. 2006 Oct;
7(3):112-7.
PMID: 17019662
Purpose: Treprostinil is approved for the treatment of pulmonary arterial hypertension (PAH) via continuous intravenous (IV) infusion. Treprostinil's anti-platelet aggregation characteristics and stability at room temperature may allow for low...
4.
McLaughlin V
Eur J Clin Invest
. 2006 Aug;
36 Suppl 3:10-5.
PMID: 16919005
Background: Pulmonary arterial hypertension (PAH) is a devastating disease of the small pulmonary arteries and arterioles, characterized by intimal fibrosis, medial hypertrophy and plexiform lesions. When untreated both the idiopathic...
5.
Sitbon O, McLaughlin V, Badesch D, Barst R, Black C, Galie N, et al.
Thorax
. 2005 Aug;
60(12):1025-30.
PMID: 16055621
Background: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a...
6.
McLaughlin V, Sitbon O, Badesch D, Barst R, Black C, Galie N, et al.
Eur Respir J
. 2005 Feb;
25(2):244-9.
PMID: 15684287
Primary pulmonary hypertension (PPH) is a progressive disease with high mortality. Administration of i.v. epoprostenol has demonstrated improved exercise tolerance, haemodynamics, and survival. The orally active, dual endothelin receptor antagonist...
7.
Rich S, McLaughlin V, ONeill W
Chest
. 2001 Oct;
120(4):1412-5.
PMID: 11591592
Angina is a common symptom of severe pulmonary hypertension. Although many theories for the source of this pain have been proposed, right ventricular ischemia is the one most commonly accepted...
8.
McLaughlin V, Rich S
Crit Care Clin
. 2001 Jul;
17(2):453-67.
PMID: 11450326
Pulmonary hypertension has many causes and therapies. A meticulous evaluation is critical. Substantial advances in medical therapy have occurred over the past decade, and the future treatment of this syndrome...
9.
Badesch D, Tapson V, McGoon M, Brundage B, Rubin L, Wigley F, et al.
Ann Intern Med
. 2000 Mar;
132(6):425-34.
PMID: 10733441
Background: Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum of disease for which no treatment has been proven effective in a randomized trial. Objective: To...
10.
Rich S, McLaughlin V
J Am Coll Cardiol
. 1999 Oct;
34(4):1184-7.
PMID: 10520810
Objectives: This study evaluated the response to prostacyclin dose reduction in patients with primary pulmonary hypertension (PPH) who developed high cardiac outputs. Background: Patients on prostacyclin require chronic upward dose...